AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10980764
Drug: Foscarnet sodium
RxNorm normalized name: Foscarnet Sodium
DrugBank: Foscarnet (DB00529)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Foscarnet sodium and ganciclovir sodium as therapy for newly diagnosed CMV retinitis
Trial: 1333071
Drug: 71.5 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 71.5 Gy in 52 fractions of 1.375 Gy given twice a day (hyperfractionated radiotherapy)
Trial: 3882307
Drug: Guanfacine, 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanfacine, 1 to 3 mg/day
Trial: 3882307
Drug: Clonidine, 0.1
RxNorm normalized name: Clonidine, 0.1 mg/24 hr transdermal film, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine, 0.1 to 0.3 mg twice a day
Trial: 31271210
Drug: Brief cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief cognitive behavioral therapy for insomnia (bCBTi)
Trial: 31271210
Drug: Treatment-as-usual for
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual for MDD and/or PTSD
Trial: 26184510
Drug: eGFR <45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eGFR <45 ml/min/1.73 m(2)
Trial: 17288694
Drug: Escitalopram 10
RxNorm normalized name: escitalopram 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram 10 mg QD
Trial: 15354280
Drug: Tegaserod 2
RxNorm normalized name: tegaserod 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegaserod 2 mg twice daily
Trial: 15354280
Drug: Tegaserod 2
RxNorm normalized name: tegaserod 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegaserod 2 mg and 6 mg
Trial: 12060615
Drug: Adoptive immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adoptive immunotherapy (AIT) with tumor-associated lymphocytes (TALs) plus low-dose cisplatinum/5-fluorouracil chemotherapy
Trial: 10102433
Drug: Natalizumab (0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natalizumab (0.03 to 3.0 mg/kg)
Trial: 10102433
Drug: Natalizumab (1-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natalizumab (1- or 3-mg/kg IV dose)
Trial: 7459895
Drug: Single large
RxNorm normalized name: Bos taurus large intestine preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single large dose of misonidazole
Trial: 7459895
Drug: Multiple smaller
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple smaller doses of misonidazole
Trial: 25664595
Drug: Tauroursodeoxycholic acid
RxNorm normalized name: tauroursodeoxycholic acid
DrugBank: Tauroursodeoxycholic acid (DB08834)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tauroursodeoxycholic acid (TUDCA) 1 g twice daily for 54 weeks
Trial: 24944242
Drug: V2R agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: V2R agonist (0.2 mg desmopressin)
Trial: 24944242
Drug: V2R antagonist
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: V2R antagonist (30 mg tolvaptan)
Trial: 22113708
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (300 mg day(‐1)) for 1 month
Trial: 10376613
Drug: Tamoxifen (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (20 mg daily for 5 years)
Trial: 9219046
Drug: Clozapine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clozapine (mean dose of 166 mg/day)
Trial: 9219046
Drug: Chlorpromazine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpromazine (mean dose of 310 mg/day)
Trial: 7524888
Drug: Busulphan (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Busulphan (1 mg/kg orally QID days -7 to -4) and cyclophosphamide (60 mg/kg IV days -3 and -2) chemotherapy
Trial: 7524888
Drug: Post-transplant G-CSF
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-transplant G-CSF
Trial: 29569449
Drug: Non-restorative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-restorative therapy
Trial: 15677778
Drug: Candesartan 16
RxNorm normalized name: candesartan 16 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan 16 mg once daily and lisinopril 20 mg once daily
Trial: 15677778
Drug: Lisinopril 40
RxNorm normalized name: lisinopril 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 40 mg once daily
Trial: 12216507
Drug: Preoperative ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative ketamine (0.15 mg/Kg i.v.)
Trial: 12216507
Drug: Postoperative ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative ketamine (0.15 mg/Kg i.v.)
Trial: 5662989
Drug: Fried onions
RxNorm normalized name: ONION
DrugBank: Onion (DB10548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fried onions (60 g)
Trial: 5662989
Drug: Boiled onions
RxNorm normalized name: ONION
DrugBank: Onion (DB10548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boiled onions (60 g)
Trial: 27206943
Drug: ETC-1002 120
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ETC-1002 120 mg
Trial: 27206943
Drug: ETC-1002 180
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ETC-1002 180 mg
Trial: 26386764
Drug: Prasugrel (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel (10 mg/day)
Trial: 23048056
Drug: High-dose clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose clopidogrel (150 mg/day)
Trial: 23048056
Drug: CYP2C19*2 noncarriers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYP2C19*2 noncarriers (high-dose clopidogrel)
Trial: 23048056
Drug: CYP2C19*2 carriers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYP2C19*2 carriers (high-dose clopidogrel)
Trial: 19745764
Drug: Everolimus 10
RxNorm normalized name: everolimus 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 10 mg oral once daily
Trial: 10459091
Drug: Warmed normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warmed normal saline solution
Trial: 9832663
Drug: Room temperature
RxNorm normalized name: ROOM DEODORIZER POWDER MENTOR #3202
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Room temperature saline solution
Trial: 8682087
Drug: Immunosuppressive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunosuppressive treatment in autoreactive forms of myocarditis
Trial: 8682087
Drug: Hyperimmunoglobulin therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperimmunoglobulin therapy
Trial: 8682087
Drug: Immunomodulating factors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunomodulating factors (e.g., ribaverin, interleukins, interferons)
Trial: 25139178
Drug: Alprazolam 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam 0.75 mg
Trial: 7480549
Drug: Alprazolam 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam 1.5 mg
Trial: 174489
Drug: Adenine arabinoside
RxNorm normalized name: Adenine
DrugBank: Adenine (DB00173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenine arabinoside ointment
Trial: 345534
Drug: Idoxuridine ointment
RxNorm normalized name: Idoxuridine
DrugBank: Idoxuridine (DB00249)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Idoxuridine ointment
Trial: 31103365
Drug: GEN-003 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GEN-003 (60 µg antigen/50 µg M2)
Trial: 31103365
Drug: GEN-003 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GEN-003 (60 µg/75 µg M2)
Trial: 28969328
Drug: Viscoelastometry guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viscoelastometry guided fresh frozen plasma (FFP) infusion
Trial: 25533539
Drug: Sodium oxybate
RxNorm normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium oxybate (SXB) titrated to effect, starting at 4.5 g/night and adjusted based on clinical response, for a duration of 12 weeks.
Trial: 21338492
Drug: Ultrasound guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound guided fascia iliaca block using levobupivacaine, plus spinal anaesthesia with hyperbaric bupivacaine containing no morphine
Trial: 21338492
Drug: Sham ultrasound
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham ultrasound guided fascia iliaca block performed with sterile saline, and spinal anaesthesia containing hyperbaric bupivacaine and 0.1 mg of spinal morphine
Trial: 16988939
Drug: Interpersonal counseling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interpersonal counseling (IPC), 1 to 6 weekly sessions, telephone-administered
Trial: 15188834
Drug: Gonadotropin-releasing hormone
RxNorm normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gonadotropin-releasing hormone agonist stimulation test (GAST)
Trial: 24084071
Drug: LABA step-up
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: LABA step-up therapy
Trial: 24084071
Drug: LTRA step-up
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: LTRA step-up therapy
Trial: 24084071
Drug: ICS step-up
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ICS step-up therapy
Trial: 30760509
Drug: Palivizumab (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palivizumab (15 mg/kg)
Trial: 8731298
Drug: Subcutaneous low
RxNorm normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous low molecular weight heparin (LMWH) 160 UaXa IC/kg/day (group IA)
Trial: 8731298
Drug: Subcutaneous low
RxNorm normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous low molecular weight heparin (LMWH) 320 UaXa IC/kg/day (group IB)
Trial: 8731298
Drug: Intravenous non-fractioned
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous non-fractioned heparin (NFH) 100UI/kg (bolus), followed by 1000UI/h
Trial: 26269615
Drug: Dulaglutide 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dulaglutide 0.5 mg/kg/dose
Trial: 26269615
Drug: Dulaglutide 1.5
RxNorm normalized name: dulaglutide 1.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dulaglutide 1.5 mg/kg/dose
Trial: 26269615
Drug: Dulaglutide 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dulaglutide 5.0 mg/kg/dose
Trial: 21995648
Drug: Colistin methanesulfonate
RxNorm normalized name: Colistin methanesulfonic acid
DrugBank: Colistimethate (DB01111)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colistin methanesulfonate sodium (CMS‐Na) 2.5 mg/kg as colistin activity, 75,000 IU/kg, twice daily repeat doses
Trial: 21995648
Drug: Colistin methanesulfonate
RxNorm normalized name: Colistin methanesulfonic acid
DrugBank: Colistimethate (DB01111)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colistin methanesulfonate sodium (CMS‐Na) 2.5 mg/kg as colistin activity, 75,000 IU/kg, single dose
Trial: 10679652
Drug: 160 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg/day megestrol acetate (low dose)
Trial: 10679652
Drug: 640 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 640 mg/day megestrol acetate (high dose)
Trial: 10072958
Drug: Domestic bendazac
RxNorm normalized name: domestic cow dander extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domestic bendazac lysine tablet
Trial: 10072958
Drug: Imported bendazac
RxNorm normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imported bendazac lysine tablet
Trial: 11072419
Drug: Caffeine 0
RxNorm normalized name: caffeine 0.65 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 0 mg (placebo)
Trial: 3602266
Drug: Caffeine 125
RxNorm normalized name: caffeine 125 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 125 mg
Trial: 8446671
Drug: Caffeine (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (any dose)
Trial: 28289240
Drug: Paracetamol (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (6 g daily for 3 days)
Trial: 21328205
Drug: Multi-sensory environment
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-sensory environment therapy (24 sessions over 12 weeks)
Trial: 16371613
Drug: 1 microg
RxNorm normalized name: Alpha 1 microglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 microg x kg(‐1) fentanyl and 0.02 mg x kg(‐1) midazolam intravenously
Trial: 12723100
Drug: New Braun
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New Braun Oral‐B Battery (D4) toothbrush
Trial: 12723100
Drug: Worn Braun
RxNorm normalized name: bran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Worn Braun Oral‐B Battery (D4) toothbrush
Trial: 8396608
Drug: 0.1% all-trans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% all-trans retinoic acid cream
Trial: 8396608
Drug: 0.1% CD271
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% CD271 gel
Trial: 3085363
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg b.d. ranitidine
Trial: 3085363
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg b.d. ranitidine
Trial: 3085363
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg nocte ranitidine for prophylaxis
Trial: 3085363
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg nocte ranitidine for prophylaxis
Trial: 28755285
Drug: Metformin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (500 mg twice daily)
Trial: 24991872
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogens (CEEs, 0.625 mg/day)
Trial: 24991872
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogens and medroxyprogesterone acetate (MPA, 2.5 mg/day)
Trial: 23469188
Drug: Clinically integrated
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinically integrated post‐graduate training programme in evidence-based medicine (5-day training including assignments, peer teaching, interactive training, lectures, brainstorming sessions)
Trial: 20962743
Drug: Higher serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher serum bicarbonate levels (20-30 mmol/l)
Trial: 20962743
Drug: Serum bicarbonate
RxNorm normalized name: BICARBONATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum bicarbonate levels near 28-30 mmol/l
Trial: 16611442
Drug: Formulation A
RxNorm normalized name: meningococcal vaccine of unknown formulation and unknown serogroups
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation A (locally manufactured SP tablet formulation, 500 mg sulfadoxine and 25 mg pyrimethamine)
Trial: 16611442
Drug: Formulation B
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation B (Fansidar, Hoffmann La Roche, Basel, Switzerland, 500 mg sulfadoxine and 25 mg pyrimethamine)
Trial: 6800389
Drug: Acebutolol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acebutolol (200 mg orally)
Trial: 19302250
Drug: Desloratadine 5
RxNorm normalized name: desloratadine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desloratadine 5 mg daily for 7 days
Trial: 9291444
Drug: Implantable cardioverter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implantable cardioverter defibrillator (16 patients) or guided drug therapy (electrophysiologically guided class I antiarrhythmic drugs = 7 patients; Holter‐guided class III antiarrhythmic drugs = 16 patients)
Trial: 9291444
Drug: Holter‐guided class
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Holter‐guided class III antiarrhythmic drugs
Trial: 7949090
Drug: Intravenous aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous aspirin (500 mg)
Trial: 7949090
Drug: Sublingual nitroglycerin
RxNorm normalized name: nitroglycerin Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual nitroglycerin (0.3 mg)
Trial: 3599793
Drug: One capsule
RxNorm normalized name: GABAdone Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One capsule t.d.s. of terpene mixture (Rowachol)
Trial: 3599793
Drug: Two capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two capsules t.d.s. of terpene mixture (Rowachol)
Trial: 24579926
Drug: Everolimus 10
RxNorm normalized name: everolimus 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 10 mg/d
Trial: 25630641
Drug: Rifampicin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin (10 mg/kg body weight)
Trial: 25630641
Drug: Rifampicin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin plus 150 mg of SQ109
Trial: 25630641
Drug: Rifampicin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin plus 300 mg of SQ109
Trial: 21372751
Drug: DTaP‐IPV‐Hep B‐PRP‐T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTaP‐IPV‐Hep B‐PRP‐T vaccine (Hexaxim)
Trial: 21372751
Drug: Pentaxim and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentaxim and Engerix B Pediatrico (Hep B monovalent) vaccines
Trial: 15367726
Drug: Levetiracetam (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam (1500 mg)
Trial: 11347331
Drug: Methylprednisolone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (200 mg, i.v., every other day, 10 doses, total course dose 2 g)
Trial: 11347331
Drug: Methylprednisolone and
RxNorm normalized name: methylprednisolone and antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone and cyclophosphamide (200 mg, i.v., on methylprednisolone-free days, 10 doses plus 200 mg i.v. once a month for 3 months, total course dose 2.6 g)
Trial: 8636283
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (goserelin, 3.6‐mg implant) for 9 months
Trial: 8636283
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (goserelin) + estrogen‐progestin replacement therapy (HRT)
Trial: 8636283
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (goserelin)
Trial: 1780418
Drug: Alprazolam (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (1.5 mg)
Trial: 1334713
Drug: 2-Deoxyglucose (2DG,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-Deoxyglucose (2DG, 50 mg/kg)
Trial: 6428577
Drug: Prednisolone 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 0.75 mg/kg/day for four weeks
Trial: 25148814
Drug: Daily remote
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily remote glucose monitoring (RGM)
Trial: 17154092
Drug: Methylprednisolone iv
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone iv pulse therapy
Trial: 17154092
Drug: Glucocorticoids (small
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucocorticoids (small doses and short periods)
Trial: 17154092
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of pulse therapy (9-12g)
Trial: 17154092
Drug: Cumulative dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cumulative dose limited to 4.5-6g
Trial: 11069196
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg risedronate daily for 2 weeks
Trial: 8619935
Drug: Adjuvant tamoxifen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant tamoxifen treatment in ER positive subgroup
Trial: 8619935
Drug: Adjuvant tamoxifen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant tamoxifen treatment in ER negative subgroup
Trial: 26888587
Drug: Continuous Positive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Positive Airway Pressure (CPAP) treatment for 4 weeks
Trial: 26888587
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (rehabilitation treatment as usual)
Trial: 24628923
Drug: OnabotulinumtoxinA (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OnabotulinumtoxinA (doses between 75 and 260 U, average 163 U per treatment cycle, administered every 12 weeks)
Trial: 18034980
Drug: Olopatadine hydrochloride
RxNorm normalized name: Olopatadine Hydrochloride
DrugBank: Olopatadine (DB00768)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olopatadine hydrochloride nasal spray, 665 mcg (OLO)